SS-31 10mg
SS-31 Specifications
Company: Hilma Biocare
Group: Injectable/Powder
Active half-life (min): 7 to 30
Subgroup: Peptide hormone
Dosage: 10 mg
Application (Men): 200-1000 mcg
Packaging: 1 vial
Contents (active ingredient): SS-31
Retains water: No
Aromatizes: No
DESCRIPTION
SS-31 (Szeto-Schiller 31), also known as MTP-131 or elamipretide, is a small cell membrane-permeable tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) belonging to the Szeto-Schiller (SS) peptide family. It acts selectively on the inner mitochondrial membrane and binds specifically to cardiolipin. Elamipretide is a pharmacological agent whose effects on mitochondria may improve physiological parameters in mitochondrial myopathies and aging.
Clinical studies demonstrate that treatment with SS-31 reverses the age-related decline in maximum mitochondrial ATP production (ATPmax) and oxidative phosphorylation (P/O) coupling, restores redox homeostasis, improves mitochondrial quality, and increases exercise tolerance without increasing mitochondrial content.
Elamipretide has been studied for the treatment of several conditions, including heart failure, macular degeneration, accelerated wound healing, and hypertension. The drug's potential is considered quite high. SS-31 is currently approved for the treatment of Barth syndrome, dry age-related macular degeneration (AMD), primary mitochondrial myopathy, and Leber hereditary optic neuropathy.
AREAS OF APPLICATION
SS-31 can accumulate in mitochondria and neutralize reactive oxygen species. The drug has pronounced antioxidant and anti-inflammatory properties. It protects mitochondria—the cellular powerhouses—from damage. SS-31 stabilizes the inner mitochondrial membrane, improves ATP production, reduces oxidative stress and inflammation, thus restoring cellular function, improving endurance, protecting the heart and brain, and slowing aging.
The medication is used in various aspects of rehabilitation and anti-aging therapy.
Cardiology : protecting the heart during ischemia and improving myocardial function.
Neurology: supporting neurons. SS-31 is potentially beneficial for Alzheimer's and Parkinson's diseases.
Metabolism: improves cellular function in cases of diabetes and obesity.
Rehabilitation and sports medicine: increases endurance and accelerates recovery.
DOSAGE
The lyophilized form of SS-31 is intended for subcutaneous administration. The recommended starting dose for preventive treatments is 1 to 2 mg per day, and for intensive recovery treatments, 4 to 10 mg per day, depending on the patient's condition and specific therapy. For a synergistic effect, SS-31 can be used in combination with MOTS-C, BPC-157, and other peptides. Consult your doctor for information on individualized dosage, administration regimen, and drug compatibility.
Contraindications
Not recommended during pregnancy or breastfeeding, as the effects on the fetus and breastfeeding have not been studied.
SIDE EFFECTS
Clinical studies have demonstrated that SS-31 is highly safe, with mild side effects. The most common (approximately 50% of cases) is a mild and transient reaction at the injection site (erythema, itching); this reaction disappears with alternating injection sites. Headache and dizziness may also occur in rare cases. These effects are also mild and transient, comparable to those of a placebo. Inform your doctor if you experience any side effects while using this medication.
SS-31 Specifications
Company: Hilma Biocare
Group: Injectable/Powder
Active half-life (min): 7 to 30
Subgroup: Peptide hormone
Dosage: 10 mg
Application (Men): 200-1000 mcg
Packaging: 1 vial
Contents (active ingredient): SS-31
Retains water: No
Aromatizes: No
DESCRIPTION
SS-31 (Szeto-Schiller 31), also known as MTP-131 or elamipretide, is a small cell membrane-permeable tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) belonging to the Szeto-Schiller (SS) peptide family. It acts selectively on the inner mitochondrial membrane and binds specifically to cardiolipin. Elamipretide is a pharmacological agent whose effects on mitochondria may improve physiological parameters in mitochondrial myopathies and aging.
Clinical studies demonstrate that treatment with SS-31 reverses the age-related decline in maximum mitochondrial ATP production (ATPmax) and oxidative phosphorylation (P/O) coupling, restores redox homeostasis, improves mitochondrial quality, and increases exercise tolerance without increasing mitochondrial content.
Elamipretide has been studied for the treatment of several conditions, including heart failure, macular degeneration, accelerated wound healing, and hypertension. The drug's potential is considered quite high. SS-31 is currently approved for the treatment of Barth syndrome, dry age-related macular degeneration (AMD), primary mitochondrial myopathy, and Leber hereditary optic neuropathy.
AREAS OF APPLICATION
SS-31 can accumulate in mitochondria and neutralize reactive oxygen species. The drug has pronounced antioxidant and anti-inflammatory properties. It protects mitochondria—the cellular powerhouses—from damage. SS-31 stabilizes the inner mitochondrial membrane, improves ATP production, reduces oxidative stress and inflammation, thus restoring cellular function, improving endurance, protecting the heart and brain, and slowing aging.
The medication is used in various aspects of rehabilitation and anti-aging therapy.
Cardiology : protecting the heart during ischemia and improving myocardial function.
Neurology: supporting neurons. SS-31 is potentially beneficial for Alzheimer's and Parkinson's diseases.
Metabolism: improves cellular function in cases of diabetes and obesity.
Rehabilitation and sports medicine: increases endurance and accelerates recovery.
DOSAGE
The lyophilized form of SS-31 is intended for subcutaneous administration. The recommended starting dose for preventive treatments is 1 to 2 mg per day, and for intensive recovery treatments, 4 to 10 mg per day, depending on the patient's condition and specific therapy. For a synergistic effect, SS-31 can be used in combination with MOTS-C, BPC-157, and other peptides. Consult your doctor for information on individualized dosage, administration regimen, and drug compatibility.
Contraindications
Not recommended during pregnancy or breastfeeding, as the effects on the fetus and breastfeeding have not been studied.
SIDE EFFECTS
Clinical studies have demonstrated that SS-31 is highly safe, with mild side effects. The most common (approximately 50% of cases) is a mild and transient reaction at the injection site (erythema, itching); this reaction disappears with alternating injection sites. Headache and dizziness may also occur in rare cases. These effects are also mild and transient, comparable to those of a placebo. Inform your doctor if you experience any side effects while using this medication.